

Patient Wallet Card

It's always a good idea to be prepared; that's why we created this Patient Wallet Card. You or your care partner can carry it at all times, so if something happens, healthcare providers will have your important information quickly at hand.

This information is not designed to replace the advice of your healthcare provider. Please reach out to your healthcare team with any questions or concerns you may have.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS).** CRS is common during treatment with EPKINLY and can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4°F (38°C) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.

Due to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule. The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

- **Neurologic problems.** EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.

Please see additional Important Safety Information on the next page. Please see [Medication Guide](#).



Please remove this card and fold along the dotted lines.

Patient Wallet Card



Patient name: _____ EPKINLY start date: _____

Name of prescribing oncologist: _____ Office phone: _____

Carry this card with you at all times. Show this card to any healthcare provider involved in your care.

Call or see your oncologist or get emergency help right away if you have any of these symptoms:

Cytokine release syndrome (CRS)

- Fever of 100.4°F (38°C) or higher
- Dizziness or light-headedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

Immune effector cell–associated neurotoxicity syndrome (ICANS)

- Trouble speaking or writing
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

Please see additional Important Safety Information before separating card or visit [EPKINLY.com](#).

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

This patient is receiving EPKINLY—which may cause serious side effects, including **cytokine release syndrome (CRS)** and **immune effector cell–associated neurotoxicity syndrome (ICANS)**.

- If CRS or ICANS is suspected, please refer to sections 2.6, 5.1, and 5.2 of the EPKINLY full Prescribing Information
- Please follow up with the prescribing oncologist about the management of this event

For more information about EPKINLY, see full Prescribing Information at [EPKINLYhcp.com](#).

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (CONT'D)

To learn about adverse reaction management for EPKINLY, scan this QR code or visit [EPKINLYhcp.com](#).



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064. EPKINLY is a trademark of Genmab A/S ©2023 Genmab A/S and AbbVie. All rights reserved. 05/2023 COM-US-EPK-000187

IMPORTANT SAFETY INFORMATION (CONT'D)

Due to the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

Do not drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

EPKINLY can also cause other serious side effects, including:

- **Infections.** EPKINLY can cause serious infections that may lead to death. Your healthcare provider will check you for symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts.** Low blood cell counts are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including **low white blood cell counts (neutropenia)**, which can increase your risk for infection; **low red blood cell counts (anemia)**, which can cause tiredness and shortness of breath; and **low platelet counts (thrombocytopenia)**, which can cause bruising or bleeding problems.

Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection.
- are pregnant or plan to become pregnant. EPKINLY may harm your unborn baby. **Females who are able to become pregnant:** Your healthcare provider should do a pregnancy test before you start treatment with EPKINLY. You should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY.
- are breastfeeding or plan to breastfeed. It is not known if EPKINLY passes into your breast milk. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea.

These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings on CRS and neurologic problems, on previous page. Please see Medication Guide.

